Author:
Mielke Johanna,Jones Byron
Publisher
Springer International Publishing
Reference61 articles.
1. Arato T (2016) Japanese regulation of biosimilar products: past experience and current challenges. Br J Clin Pharmacol 82(1):30–40
2. Barlas S (2017) FDA guidance on biosimilar interchangeability elicits diverse views: current and potential marketers complain about too-high hurdles. Pharm Ther 42(8):509
3. Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, Manfredi M, Parisi S, Fusaro E, Batticciotto A et al (2017) Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res 65(1):419–422
4. Berkowitz SA (2017) Analytical characterization: structural assessment of biosimilarity, Chap 2. In: Endrenyi L, Declerck P, Chow SC (eds) Biosimilar drug product development. CRC Press, Boca Raton, pp 15–82
5. Bewesdorff M (2016) Biosimilars in the U.S. – the long way to their first approval. Master of drug regulatory affairs, Rheinischen Friedrich-Wilhelms-Universitat Bonn